Table 1.
Distribution of CAT, GPX, MnSOD, GSTP1, GSTM1, and GSTT1 genotypes among AML patients and controls.
| Polymorphism | AML patients n (%) |
Controls n (%) |
p value, OR (95% CI) AML versus controls |
|---|---|---|---|
| CAT C262T | |||
| CC | 55 (53.9) | 161 (53.1) | Reference |
| CT | 41 (40.2) | 123 (40.6) | 0.985, 0.98 (0.61–1.56) |
| TT | 6 (5.9) | 19 (6.3) | 0.985, 0.92 (0.35–2.43) |
| CT + TT | 47 (46.1) | 142 (46.9) | 0.89, 0.969 (0.618–1.519) |
| GPX1 Pro198Leu | |||
| Pro/Pro | 3 (2.9) | 34 (11.2) | Reference |
| Pro/Leu | 28 (27.5) | 190 (62.7) | 0.588, 1.670 (0.480–5.80) |
| Leu/Leu | 71 (69.6) | 79 (26.1) | <0.0001, 10.186 (2.997–34.622) |
| Pro/Leu + Leu/Leu | 99 (97.1) | 269 (88.8) | 0.012, 4.171 (1.252–13.886) |
| MnSOD Ala16Val | |||
| Ala/Ala | 24 (23.5) | 54 (17.8) | Reference |
| Ala/Val | 60 (58.8) | 168 (55.4) | 0.464, 0.803 (0.457–1.413) |
| Val/Val | 18 (17.6) | 81 (26.7) | 0.074, 0.50 (0.248–1.009) |
| Ala/Val + Val/Val | 78 (76.5) | 249 (82.2) | 0.206, 0.705 (0.409–1.214) |
| GSTP1 Ile105Val | |||
| Ile/Ile | 39 (38.2) | 205 (67.7) | Reference |
| Ile/Val | 57 (55.9) | 88 (29.0) | <0.001, 3.405 (2.111–5.491) |
| Val/Val | 6 (5.9) | 10 (3.3) | 0.0393, 3.154 (1.083–9.183) |
| Ile/Val + Val/Val | 63 (61.8) | 98 (32.3) | <0.0001, 3.379 (2.120–5.386) |
| GSTM1 | |||
| Present | 43 (42.2) | 125 (41.3) | Reference |
| Null | 59 (57.8) | 178 (58.7) | 0.873, 0.964 (0.612–1.518) |
| GSTT1 | |||
| Present | 78 (76.5) | 240 (79.2) | Reference |
| Null | 24 (23.5) | 63 (20.8) | 0.56, 1.172 (0.686–2.002) |